Navigation Links
Cadila to Commence Phase I Clinical Trials On ZYH2

Cadila Healthcare Ltd today said it has received approval from Drug Controller General of India (DCGI) to conduct Phase I clinical trials on its New Molecular Entity// (NME) - ZYH2, used for treating diabetes.

In pre-clinical studies on 'ZY H2' displayed that it has the potential to improve insulin resistance and lower blood glucose in diabetic conditions without causing hypoglycemia, the company informed the Bombay Stock Exchange.

It also works favourably to lower the elevated lipid levels and the pre-clinical studies on ZYH2 indicate that this NME may be more effective for diabetics, it added.

The shares of the company closed at Rs 545.50, up 0.06 per cent at the BSE.

Source:PTI News
'"/>




Page: 1

Related medicine news :

1. Zydus Cadila and Kopran in strategic alliance
2. Cadila gets US FDA approval for Promethazine tablets
3. Cadila Gets Tentative USFDA Nod For Pravastatin Sodium Tablets
4. Face Transplants To Commence In The UK
5. Pfizer Commences Its Advertising for Celebrex with All the Warnings
6. Natco Pharma Commences Production At Dehradun Unit
7. Chinas First Gay Health Clinic Commences Operations
8. Mental Health - NHS Trust Commences Specialist Transition Service
9. SARS-Free Taiwan to Mark End Phase of Global Fight
10. Spray on contraceptive clears Phase I trial
11. Phase 3 trials of two multi-kinase inhibitors against cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/6/2016)... ... 06, 2016 , ... Research has shown that building shame ... frequency and level of relapse. , At the 2016 iaedp Symposium, ... explore the critical tasks of the recovery phase and beyond including relapse prevention ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior ... that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will ... , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food ...
(Date:2/5/2016)... Santa Rosa, CA (PRWEB) , ... February 05, ... ... are pleased to announce the addition of micro-needling services in their Napa Valley ... appearance. The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... once again host, Swirl, A Wine Tasting Event at the La Gorce Country ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Regular gym users ... themselves having to wait longer to access the treadmills. It’s a predictable trend. After ... to lose weight and get in shape by joining gyms, starting new walking or ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Frontier Pharma: Chronic Obstructive Pulmonary Disease ... Chronic Obstructive Pulmonary Disease (COPD) is ... the airways and lungs. Persistent breathing difficulties and ... one of the leading causes of morbidity and ... COPD is linked to cumulative exposure to risk ...
Breaking Medicine Technology: